NasdaqGM - Nasdaq Real Time Price USD

Harrow, Inc. (HROW)

25.55

+0.48

+(1.91%)

At close: April 25 at 4:00:02 PM EDT

25.30

-0.25

(-0.98%)

After hours: April 25 at 7:57:56 PM EDT

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announced a partnership with Harrow (Nasdaq: HROW), a leading North American eyecare company, to launch an authorized generic of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension), which treats and relieves bacterial eye infections.

PR Newswire 2 days ago

HROW
+1.91%
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Harrow Inc (HROW) reports an impressive 84% increase in Q4 revenue, driven by strong product performance and strategic programs, despite challenges in cash flow and reporting.

GuruFocus.com 5 days ago

HROW
+1.91%
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients

NASHVILLE, Tenn., April 10, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an expansion of its VEVYE® Access for All ("VAFA") program to include patients currently prescribed Klarity-C Drops®, a compounded cyclosporine 0.1% product manufactured and distributed by ImprimisRx®, Harrow’s compounding subsidiary. Since its launch on March 17, 2025, VEVYE Access for All has simplified dry eye therapy for eligible patients by eliminating access bar

Business Wire 16 days ago

HROW
+1.91%
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives

Harrow Inc (HROW) reports an 84% increase in Q4 revenue, driven by strong product performance and strategic programs, despite challenges in reporting and cash flow management.

GuruFocus.com 28 days ago

HROW
+1.91%
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

NASHVILLE, Tenn., March 27, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2024. The Company also posted its fourth quarter Letter to Stockholders and corporate presentation to the "Investors" section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future ex

Business Wire 30 days ago

HROW
+1.91%
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

NASHVILLE, Tenn., March 27, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its fourth quarter and audited financial results for the year ended December 31, 2024, on Thursday, March 27, 2025, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Frida

Business Wire 30 days ago

HROW
+1.91%
Harrow And 2 Insider Picks For Growth Potential

As the U.S. stock market navigates through a period of volatility marked by tariff announcements and tech sector selloffs, investors are keenly observing economic indicators for signs of potential recessionary pressures. Amidst this backdrop, stocks with high insider ownership often attract attention as they can signal confidence from those closest to the company's operations and strategy. In today's market environment, such insider stakes might suggest resilience and growth potential in...

Simply Wall St. 30 days ago

KLG

LWAY

HROW
+1.91%
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

NASHVILLE, Tenn., March 24, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Harrow’s transitional pass-through application for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and for the treatment of ocular infl

Business Wire last month

HROW
+1.91%
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

NASHVILLE, Tenn., March 17, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced unaudited preliminary financial results for the fourth quarter and year ended December 31, 2024, as well as revenue guidance for 2025. Although Harrow was initially scheduled to release its audited financial results today, the Company’s new independent auditor requires additional time to audit Harrow’s financial presentation. As a result, Harrow is delaying its earnin

Business Wire last month

HROW
+1.91%
Harrow Launches VEVYE® Access for All

NASHVILLE, Tenn., March 17, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today introduced VEVYE® Access for All, a groundbreaking initiative that underscores Harrow’s long‑standing commitment to access and affordability. This program, which is now available through our PhilRx specialty pharmacy partner, guarantees access to VEVYE (cyclosporine ophthalmic solution) 0.1% for eligible patients and health plans for $59, ensuring that every patient can afforda

Business Wire last month

HROW
+1.91%
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

NASHVILLE, Tenn., March 11, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the execution of a five-year strategic supply and development ("SSD") agreement for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and the treatment of ocular inflammatory conditions that are unresponsive to t

Business Wire last month

HROW
+1.91%
Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

NASHVILLE, Tenn., March 03, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2024, on Monday, March 17, 2025, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, March

Business Wire last month

HROW
+1.91%
US Growth Companies With High Insider Ownership To Watch

As U.S. stock futures point to a higher open, investors are keenly watching the market's response to Nvidia's earnings report, hoping for a break from the recent four-day slump in major indices. In this environment of heightened anticipation and economic uncertainty, growth companies with high insider ownership can offer unique insights into potential resilience and alignment of interests between company leaders and shareholders.

Simply Wall St. last month

GAMB

HROW
+1.91%
SMWB
Harrow (NASDAQ:HROW) shareholders have earned a 40% CAGR over the last five years

Harrow, Inc. ( NASDAQ:HROW ) shareholders might be concerned after seeing the share price drop 28% in the last quarter...

Simply Wall St. 2 months ago

HROW
+1.91%
Reddit initiated, Cigna downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top Upgrades: Evercore ISI upgraded CarMax (KMX) to Outperform from In Line with a price target of $110, up from $90. The firm sees the company’s improving comp and share trends persisting amid a favorable industry backdrop. Exane BNP Paribas upgraded Array Technologies (ARRY) to Neutral from Underperform with a $9 pr

TipRanks 2 months ago

MTCH

CI

TTEK
Harrow Partners with Cencora to Launch "Harrow Cares" Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

NASHVILLE, Tenn., January 27, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its "Harrow Cares" program through a strategic partnership with Cencora (NYSE: COR). Harrow Cares delivers a comprehensive suite of high‑quality access and affordability services, enhancing support for retina specialists, their staff, and patients. Through a state-of-the-art patient support services hub, Harrow Cares ensures seamless enrollment, rapid

Business Wire 2 months ago

HROW
+1.91%
3 US Growth Companies With High Insider Ownership Seeing Up To 39% Revenue Growth

As the U.S. stock market continues its upward trajectory, buoyed by strong earnings reports and investor optimism, major indices like the Dow Jones Industrial Average and the S&P 500 are approaching record highs. In this environment of growth and opportunity, companies with high insider ownership can be particularly appealing as they often signal confidence from those most familiar with their operations, especially when these companies are experiencing significant revenue growth.

Simply Wall St. 3 months ago

HROW
+1.91%
PDFS

GCT
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

NASHVILLE, Tenn., January 07, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophtha

Business Wire 3 months ago

HROW
+1.91%
3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth

As the U.S. stock market inches higher in a holiday-shortened session, with indices like the Nasdaq Composite and S&P 500 posting modest gains, investors are keeping a close eye on growth stocks that demonstrate robust potential amid fluctuating economic conditions. In this context, companies with high insider ownership can be particularly appealing, as significant insider stakes often signal confidence in the company's future prospects and alignment of interests between management and...

Simply Wall St. 3 months ago

KRYS

AMRC

HROW
+1.91%
US Growth Stocks With High Insider Ownership To Watch

As the U.S. stock market continues to reach new heights, with the Dow Jones Industrial Average closing at a record high and major indices posting weekly gains, investors are increasingly focused on identifying promising opportunities in this thriving environment. In such a robust market, stocks of growth companies with high insider ownership can be particularly appealing due to their potential for alignment between management and shareholder interests, offering a compelling case for those...

Simply Wall St. 4 months ago

CTV

CTV-WS

SPOT

Performance Overview

Return	HROW	S&P 500 (^GSPC)
YTD	-23.85%	-6.06%
1-Year	+155.50%	+9.44%
3-Year	+287.71%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Harrow, Inc. (HROW)

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Harrow And 2 Insider Picks For Growth Potential

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Harrow Launches VEVYE® Access for All

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

US Growth Companies With High Insider Ownership To Watch

Harrow (NASDAQ:HROW) shareholders have earned a 40% CAGR over the last five years

Reddit initiated, Cigna downgraded: Wall Street’s top analyst calls

Harrow Partners with Cencora to Launch "Harrow Cares" Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

3 US Growth Companies With High Insider Ownership Seeing Up To 39% Revenue Growth

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth

US Growth Stocks With High Insider Ownership To Watch

Performance Overview